Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by fredgoodwinsonon Apr 24, 2022 6:51pm
203 Views
Post# 34627664

RE:RE:RE:RE:RE:RE:RE:RE:Determining a Company’s Value - Old School

RE:RE:RE:RE:RE:RE:RE:RE:Determining a Company’s Value - Old SchoolRumpl - long been here for the prospective treatment of a range of cancers both by TLD-1433 and other of Sherri`s metal-based compounds which in terms of unconditional exclusivity may effectively mean Rutherrin.

There now looks to be no prospect of addressing any further cancers in this way in the foreseeable future and this is bitterly regretted - all the more so as Roswell were giving the most serious consideration to the use of TLD-1433 in lung cancer and mesothelioma.

Would TLT have the slightest difficulty in finding partners if Rutherrin has the ability to treat deep seated cancers non-invasively via low dose x-ray as repeatedly suggested in their newsletters?

Will not guess as to why after so many years`preclinical due diligence the Company so quickly rowed back from using Rutherrin in humans but with the possible exception of the present Trial you are certainly right in saying that TLT`s ACT hasn`t gone anywhere.




<< Previous
Bullboard Posts
Next >>